Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
about
Schizophrenia relapse, patient considerations, and potential role of lurasidoneA review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia.On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not.Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil.A review of new atypical antipsychotic launches in the United States.Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medicationsPhysician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.Drug safety evaluation of ziprasidone.Lurasidone for schizophrenia: what's different?Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.Lurasidone in schizophrenia: new information about dosage and place in therapy.Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.Safety profile of iloperidone in the treatment of schizophrenia.Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia, but vary in their tolerability.Asenapine review, part II: clinical efficacy, safety and tolerability.Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism.The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?Role of sublingual asenapine in treatment of schizophrenia.Lack of tolerable treatment options for patients with schizophrenia.Asenapine: a new antipsychotic option.Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USABrexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to bCariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
P2860
Q26738850-9D9C85CC-6EBD-45D7-AE11-537CEEF5D706Q30353864-DEB6F691-E9E7-4E76-90A6-D5B6A44816ABQ34224372-865FA2D5-9200-4EBC-93C2-DC85608973EEQ34226261-92E649A7-F7E9-4C52-8323-7A97008983EEQ34322714-1E3720BF-CCEF-491A-8999-BA1E2A61F3A9Q34325164-955DD94F-BF50-4D34-9F8D-BCDF238F601CQ34501911-AF31A749-285F-4FDD-9C38-7C267E73F220Q34527733-9E6F810C-0E2C-4A4A-A5E3-EDA8F8510AEDQ34542303-D194AB71-641A-4CF9-AE09-94DD3982F7F7Q34628304-AD952774-1CDC-43E2-A4FF-955AB23D5556Q35776860-41C61EA8-91A0-4D06-BC6F-A72F8FF46E6AQ36279100-9564F332-12C9-472B-84F0-05B8703472FFQ37376779-0C330CFD-C49F-4730-8086-D87D21A8D5F4Q37804880-55DEF77C-CD1D-4845-B708-8FD577F939ADQ37815561-06C5780B-73AC-4665-9467-F56321EDC0F6Q37844574-706C07B1-3D54-4EA4-9F86-5F6AB319D19BQ37987985-3C8885D2-4525-4176-BF38-47F47C191362Q38013250-27526439-5283-414E-8F6C-69EF8F24CF97Q38045797-649C50D7-4997-47C2-AA36-7D849AAB15AEQ38070179-A9667A0A-C4F8-4550-9680-187AF66639C0Q38085441-A2C52B48-FD10-4344-B2A0-BF30F630700DQ38100267-4D6193A3-41DB-4203-8BDD-C5F3B4D936BBQ38125213-D1A7BE38-7C14-4603-8C6A-60B7E07D9848Q38160942-7274807B-937D-4864-8CF0-85B1FAC13FA5Q38171794-66A635D5-D10B-4B32-88CE-1330DC639806Q38209081-09CC363E-AE17-4FAB-9D11-FCA0213B9F45Q38209103-00D3E8ED-091D-407F-855C-60FDA7367A3DQ38592139-97967B67-4987-45BB-960E-3EE8336A83FAQ39009497-7D418473-D524-4139-8E6C-050BF27C078BQ39065466-7868FAF9-FD52-4E84-BE13-9A66757B9CBBQ41822209-6267290D-EB18-4811-BE61-81D13D86A2AAQ42120078-5171488E-F41F-473B-836D-D27E711A8B74Q48788366-1EE689AC-F1E9-4D61-8F58-F10EE6FEE754Q54217848-A7FD773C-0994-4125-8A90-B14C7F31719EQ56790547-B14342D1-5884-46B7-82E3-CE82D963BF6AQ56790616-F211EC79-187D-4A1B-BD25-450061B5E079Q57483192-C977DE2A-005F-4633-A859-597910D59415
P2860
Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Oral antipsychotics for the tr ...... should drive decision-making.
@en
Oral antipsychotics for the tr ...... should drive decision-making.
@nl
type
label
Oral antipsychotics for the tr ...... should drive decision-making.
@en
Oral antipsychotics for the tr ...... should drive decision-making.
@nl
prefLabel
Oral antipsychotics for the tr ...... should drive decision-making.
@en
Oral antipsychotics for the tr ...... should drive decision-making.
@nl
P2860
P1476
Oral antipsychotics for the tr ...... should drive decision-making.
@en
P2093
Jan Volavka
P2860
P304
P356
10.1517/14656560903061309
P407
P577
2009-08-01T00:00:00Z